Professor Allan Young holds the Chair of Mood Disorders and is Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London, where he is also Head of School for Academic Psychiatry, United Kingdom (UK). Prof Young is the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre (BRC) Cluster and Theme lead in the Translational Therapeutics Cluster. Prof Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic. He has held academic appointments at Oxford University; Newcastle University (latterly holding the Chair of General Psychiatry at Newcastle), University of British Columbia in Vancouver, Canada, where he held the Leading Edge Endowment Fund Endowed Chair in Research in the Department of Psychiatry and was also the Director of the Institute of Mental Health and Imperial College London, where he held the Chair of Psychiatry and was Director of the Centre for Mental Health.

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, the Stanley Medical Research Institute, the Canadian Institutes for Heath Research (CIHR), the National Institutes of Health (USA), and numerous other funding agencies. He has published over 400 peer-reviewed publications and a number of books about psychopharmacology and affective disorders including Bipolar Disorders: Basic Mechanisms and Therapeutic Implications (2nd Ed) with J.C. Soares, and Practical Management of Bipolar Disorder with I.N. Ferrier and E. Michalak (Cambridge University Press, 2010).

Professor Young is a member of several editorial boards and is a member of numerous professional and scientific societies. He is immediate Past-President of the International Society for Affective Disorders, President of the British Association of Psychopharmacology and the immediate past Chair of the Special Committee for Psychopharmacology of the Royal College of Psychiatrists. He is also a Trustee of the patient and family charity Bipolar UK. The national charity dedicated to supporting individuals with the much misunderstood and devastating condition of bipolar, their families and carers.  Prof Young is a trustee of The Drug Safety Research Unit (DSRU), an independent academic unit internationally respected for its work in Pharmacovigilance, Pharmacoepidemiology, Risk Management and Training Services for over 30 years. http://www.dsru.org/ .

Professor Young was recently ranked as one of the world's leading scientific minds in the field of Psychiatry and Psychology, according to the 2021 Thomson Reuters Highly Cited Researchers list.  In all of science, a total of over 3,000 researchers worldwide earned this distinction and the academics listed rank among the top 1% most cited for their subject field and year of publication, a mark of exceptional impact. (see: https://www.kcl.ac.uk/news/ioppn-researchers-feature-in-2021-highly-cited-researcher-list )

Declaration of Interests

1. Have you, in the past three years, had patents or inventions from which you may derive personal benefit in the area of psychopharmacology?

No

1. Have you, in the past three years, had ownership or part ownership of a company with interests in the area of psychopharmacology? (This would include holding the shares of major companies in one's own name, or those of dependent family members.)

No

1. Have you, in the past three years, accepted a personal retainer from any company with an interest in psychopharmacology?

No

1. Have you, in the past three years, acted as a consultant to any company with an interest in psychopharmacology?

Johnson & Johnson & Livanova

1. Have you, in the past three years, acted as an expert witness, either friendly or hostile, to any company with an interest in psychopharmacology?

Acted as an expert witness to GSK

1. Have you, in the past three years, held a research grant from any company with an interest in psychopharmacology?

Janssen, Compass, Livanova, 

1. Have you, in the past three years, had membership of the speakers' bureau for any company?

No

1. Have you, in the past three years, accepted paid speaking engagements in industry supported symposia?

Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders Astrazenaca, Eli Lilly, Janssen, Lundbeck, Sunovion, Servier, Livanova, Sage, Sandoz, Novartis

1. Have you, in the past three years, accepted travel or hospitality NOT related to a speaking engagement?

No

1. Have you, in the past three years, recruited patients for industry-sponsored studies?

Janssen, COMPASS, Livanova, Novartis

1. If there is anything else you feel it necessary to disclose, please provide details below:

Employed by King’s College London; Honorary Consultant SLaM (NHS UK) Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders Astrazenaca, Eli Lilly, Janssen, Lundbeck, Sunovion, Servier, Livanova, Novartis

Principal Investigator on ESKETINTRD3004: “An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression.”

Principal Investigator on “The Effects of Psilocybin on Cognitive Function in Healthy Participants”

Principal Investigator on “The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD)”

UK Chief Investigator for Novartis MDD study MIJ821A12201

No share holdings in pharmaceutical companies Lead Investigator for Embolden Study (AZ), BCI Neuroplasticity study and Aripiprazole Mania Study Investigator initiated studies from AZ, Eli Lilly, Lundbeck, Wyeth Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK)